Introduction {#sec1_1}
============

Pars plana vitrectomy (ppv) is a proven and basically safe procedure with a low incidence of complications \[[@B1], [@B2]\]. However, serious adverse events can and do occur, the most serious complications being endophthalmitis \[[@B3]\], hemorrhages and nonarteritic anterior ischemic optic neuropathy (NAION), a potentially blinding condition \[[@B4]\]. An investigation in a random sample of 5% of the American Medicare beneficiaries \[[@B5]\] over a period of 12 years (1994--2005) yielded an incidence of approximately 7% for postprocedural blindness after ppv without an appreciable trend over time. Whereas endophthalmitis is widely considered and investigated in the literature concerning post-ppv complications \[[@B1], [@B2], [@B3]\], the incidence of postprocedural loss of vision due to NAION appears to be somewhat underreported. Following the concept of vascular occlusion as a key factor in sudden blindness, the conventional mainstay for the treatment of postsurgical loss of vision is the systemic administration of corticosteroids and anticoagulants, e.g. acetylsalicylic acid \[[@B6], [@B7], [@B8]\]. However, there is no generally accepted, well-proven treatment for NAION currently \[[@B9]\]. In the past decade, a number of novel protein-based direct thrombin inhibitors became available for the treatment of diseases associated with undesired blood clotting. One of those agents is dabigatran etexilate, presently approved for the prophylaxis of venous thrombosis after hip or knee arthroplasty and stroke in patients with atrial fibrillation \[[@B10]\]. After all conventional methods of reversing the visual loss in our patient had failed, we resorted to a therapeutic trial of dabigatran etexilate, and the results are reported here.

Case Presentation {#sec1_2}
=================

A 46-year-old Caucasian female underwent ppv of the right eye with endolaser treatment and C~2~F~6~ (hexafluoroethane) gas tamponade as per the current guidelines \[[@B11]\] for retinal detachment. After the procedure, the vision of the treated eye was practically lost, and the patient was only able to distinguish hand movements. The retina was flat and the macula well attached (fig. [1](#F1){ref-type="fig"}). The afferent pupillary defect (APD) was positive, and perimetry revealed a severe loss of the visual field (fig. [2](#F2){ref-type="fig"}). The administration of a conventional therapeutic regimen \[consisting of prednisolone (100 mg/day for 3 days, 80 mg/day for 3 days, 60 mg/day for 3 days, 40 mg/day for 3 days, and 20 mg/day for 3 days) and acetylsalicylic acid (100 mg)\] improved visual acuity only marginally to logMAR 1,4 (fig. [3](#F3){ref-type="fig"}) with positive APD.

Since pronounced corticosteroid side effects (sleeplessness, facial edema, restlessness, sweating and tachycardia) burdened the patient and the treatment showed practically no effect, we decided to try to improve her vision with the administration of dabigatran etexilate (2 × 110 mg), a novel direct thrombin inhibitor, 24 days after the initiation of the prednisolone/acetylsalicylic acid treatment. Promptly after the first administration, visual acuity improved to logMAR 1,0 and continued to improve to logMAR 0,4 (fig. [3](#F3){ref-type="fig"}). APD was still positive. Perimetry done 26 days afterwards showed a marked improvement in central sensitivity from 7 to 25 and 21 dB, respectively; the nasal part of the visual field also showed an increase in sensitivity (fig. [4](#F4){ref-type="fig"}), and APD was negative.

Discussion {#sec1_3}
==========

Strictly speaking, the diagnosis of NAION requires the exclusion of arteritic alterations, usually by temporal artery biopsy. However, a sudden loss of vision after ocular surgery without signs of retinal detachment or other intraocular alterations strongly suggest ischemic neuropathy, and tentative diagnosis and treatment are warranted \[[@B4]\]. Since NAION is not a disease as such but rather the common endpoint of a large number of local and systemic conditions, there is no established standard therapy \[[@B9]\]. However, systemic corticosteroids in combination with anticoagulation to reduce swelling and improve venous blood flow are basically accepted modalities. When this approach failed in the present case, we resorted to the off-label administration of a novel direct thrombin inhibitor, resulting in a dramatic recovery of visual function.

It would be premature to construe this as a direct medication effect, though. NAION is known to show spontaneous remission in approximately 40% of the cases \[[@B4]\], but this assumption notwithstanding, improvement of blood flow is an accepted measure whose indication to preserve or restore vision is undisputed. Therefore, the striking improvement of vision after the administration of dabigatran etexilate in the present case may warrant a systematic clinical trial of a combination of corticosteroids and dabigatran etexilate in comparison with (for instance) warfarin as is common practice under different indications for anticoagulation \[[@B12], [@B13], [@B14]\]. However, when ophthalmologists consider the administration of dabigatran etexilate for NAION, certain peculiarities and disadvantages of the drug (such as the lack of an antidote \[[@B12], [@B15]\]) need to be borne in mind to avoid potential hazards.
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![Optical coherence tomography 19 days postoperatively.](cop-0005-0262-g01){#F1}

![Visual field before the administration of dabigatran etexilate (Octopus 101; Haag-Streit Deutschland GmbH, Wedel, Germany). Duration 4 min 53 s, 132 targets, ambient luminance 4 Asb.](cop-0005-0262-g02){#F2}

![Development of visual acuity over time.](cop-0005-0262-g03){#F3}

![Visual field after the administration of dabigatran etexilate \[duration 5 min 52 s, 144 targets, ambient luminance 4 Asb (for examination parameters, see text)\].](cop-0005-0262-g04){#F4}
